Blood
Articles in this Issue
Thrombotic thrombocytopenic purpura-related mortality trends among the United States population: A retrospective study using the CDC wonder database
Abstract Background Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy...
Spatial multi-omics reveal distinct immunosuppressive lipid-laden macrophages in primary CNS lymphoma compared to systemic DLBCL
Abstract Introduction Primary central nervous system lymphoma (PCNSL) is an aggressive B-cell lymphoma exhibiting unique central nervous sys...
Impact of iron deficiency anemia on outcomes in postpartum hemorrhage: Insights from a national inpatient sample analysis
Abstract Background: Postpartum hemorrhage (PPH) is a leading contributor to maternal morbidity and mortality worldwide. Iron deficiency ane...
Sociodemographic determinants of survival in acute lymphoblastic leukemia: A 20-year SEER-based analysis
Abstract Introduction Despite significant advancements in therapeutic strategies, acute lymphoblastic leukemia (ALL) continues to present a...
Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL)
Abstract BACKGROUND Early disease progression within 24 months following chemoimmunotherapy (CIT) is an established adve...
Disparities in treatment timing and access to care in chronic lymphoytic leukemia
Abstract Background: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries. Advances...
Prophylactic intravenous immunoglobulin in patients receiving BCMA-targeted bispecific antibody therapy for multiple myeloma: A systematic review and meta-analysis
Abstract Introduction Patients with relapsed/refractory multiple myeloma treated with bispecific antibodies (bsAbs), either targeting B-cell...
In Vivo RNA delivery by targeted lipid nanoparticles enable gene editing in hematopoietic stem cells and T cells
Abstract Non-viral in vivo genetic medicines promise novel and potentially curative therapies with broader patient access than ex vivo gene...
Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma
Abstract Background: Teclistamab (Tec) is a BCMA-directed T-cell engaging bispecific antibody for relapsed/refractory multiple myeloma (RRMM...
Blinatumomab vs. chemotherapy in pediatrics B-cell ALL: A meta-analysis of randomized controlled trials
Abstract Background: B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric cancer, comprising up to 25% of childhood mali...
Requirements for achievement of treatment-free remission in long-term survivor of multiple myeloma
Abstract Background Establishing a curative strategy for multiple myeloma (MM) remains a significant challenge. While cure is defined as a s...
Pharmacodynamic biomarkers in people with hemophilia A receiving multiple ascending doses of NXT007
Abstract Background: NXT007 is a bispecific, monoclonal antibody that mimics the function of activated factor (F)VIII. NXT007 was engineered...
An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone – the IBIS study amarc 20-01.
Abstract Background: Approximately 20% of NDMM patients (pts) demonstrate early therapeutic resistance, manifesting as primary refractorines...
High-frequency monitoring of clonal dynamics in MPN using saliva and peripheral blood during interferon therapy
Abstract Interferon-alpha (IFNα) remains the only cytoreductive therapy for myeloproliferative neoplasms (MPNs) capable of inducing molecula...
Minimal residual disease assessment in hematologic malignancies: A systematic review highlighting global disparities and limited evidence from low- and middle-income countries
Abstract Background: Minimal residual disease (MRD) is an extremely important prognostic factor in hematological malignancies, with numerous...
Improved outcomes with low-dose hypomethylating agent plus venetoclax as post-transplant maintenance in patients undergoing reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for myeloid malignancies
Abstract Introduction: Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly in patients receiving redu...
A study on the efficacy, safety and mechanism of venetoclax combined with CAR-T targeting CLL1 in the treatment of Acute Myeloid Leukemia
Abstract Objective: Venetoclax (VEN) monotherapy exhibits limited clinical benefits in refractory/relapsed acute myeloid leukemia (r/r AML)....
Effectiveness of sirolimus for pediatric autoimmune cytopenias and factors associated with clinical response
Abstract Introduction Pediatric autoimmune cytopenias (pAICs) encompass a variety of disorders leading to destruction of...
Factors influencing patient treatment selection among bispecific antibodies for relapsed/refractory multiple myeloma (RRMM): A mixed methods study
Abstract Background Novel immunotherapies such as bispecific antibodies (BsAbs) are rapidly changing the treatment landscape for RRMM, with...
DLBCL tumor microenvironment archetype and CD4+ T cell conversion to cytotoxic cells are required for response to glofitamab
Abstract INTRODUCTION Glofitamab (glofit) is a T cell engager (TCE), which binds CD20 on the DLBCL cell and the CD3 molecule on T cells to dr...
Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study
Abstract INTRODUCTION: Indolent MCL (iMCL) is an infrequent presentation of the disease with variable incidence across different studies, and...
Venous thromboembolism in adults with sickle cell disease: A national inpatient sample analysis (2016–2020)
Abstract Background Patients with sickle cell disease (SCD) are at increased risk for venous thromboembolism (VTE). Desp...
Arginine methylation on MSI2 drives resistance to PRMT1/5 inhibitors in lymphoma, controls translation and dictates cell fate
Abstract Dysregulation of protein arginine methyltransferases (PRMTs) is implicated in many cancers. MTAP-deleted tumors are selectively sen...
CLPTM1L: A candidate therapeutic target in multiple myeloma
Abstract Introduction: With over 30,000 new cases annually, multiple myeloma (MM) is the second most common blood cancer in the United State...
Germline variants and their role in the pathogenesis of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) in adult lymphoma patients
Abstract Introduction: IEC-HS is a rare but potentially fatal adverse event following chimeric antigen receptor (CAR) T cell and other IEC-e...